Molecular determinants of head and neck cancer /
Saved in:
| Edition: | Second edition. |
|---|---|
| Imprint: | Cham : Humana Press, 2018. |
| Description: | 1 online resource |
| Language: | English |
| Series: | Current cancer research Current cancer research. |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/11690115 |
MARC
| LEADER | 00000cam a2200000Ii 4500 | ||
|---|---|---|---|
| 001 | 11690115 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 180807s2018 sz o 000 0 eng d | ||
| 005 | 20240701203254.3 | ||
| 015 | |a GBB8N9083 |2 bnb | ||
| 016 | 7 | |a 019170810 |2 Uk | |
| 019 | |a 1048284577 | ||
| 020 | |a 9783319787626 |q (electronic bk.) | ||
| 020 | |a 3319787624 |q (electronic bk.) | ||
| 020 | |z 9783319787619 | ||
| 020 | |z 3319787616 | ||
| 035 | |a (OCoLC)1047959917 |z (OCoLC)1048284577 | ||
| 035 | 9 | |a (OCLCCM-CC)1047959917 | |
| 037 | |a com.springer.onix.9783319787626 |b Springer Nature | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d GW5XE |d EBLCP |d YDX |d OCLCF |d UAB |d MERUC |d MERER |d OTZ |d LVT |d U3W |d UKMGB |d CAUOI |d ESU |d COO |d OCLCQ | ||
| 049 | |a MAIN | ||
| 050 | 4 | |a RC280.H4 | |
| 066 | |c (S | ||
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 245 | 0 | 0 | |a Molecular determinants of head and neck cancer / |c Barbara Burtness, Erica A. Golemis, editors. |
| 250 | |a Second edition. | ||
| 264 | 1 | |a Cham : |b Humana Press, |c 2018. | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Current cancer research | |
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed August 9, 2018) | |
| 505 | 0 | |a Intro; Contents; Chapter 1: Overview: The Pathobiology of Head and Neck Cancer; References; Chapter 2: Targeting the ErbB Family in Head and Neck Cancer; 2.1 Introduction; 2.2 Regulation of EGFR and the ErbB Family in Normal Cells; 2.2.1 Ligand Binding and Dimerization: Activation of ErbB Proteins in Normal Cells; 2.2.2 ErbB Trafficking and Other Mechanisms to Limit EGFR Function in Normal Cells; 2.3 Causes and Consequences of Altered EGFR/ErbB Function in SCCHN; 2.3.1 Overexpression of EGFR and Its Ligands | |
| 505 | 8 | |a 2.4.3 Targeting Critical EGFR/ErbB Effectors2.4.4 EGFR/ErbB2 and Immunotherapy/Immune Response; 2.5 Mechanisms of Resistance to Anti-EGFR Therapies; 2.5.1 EGFR-Intrinsic Resistance; 2.5.2 Elevated Expression of ErbB Family Members; 2.5.3 VEGF Expression; 2.5.4 STAT3 Expression; 2.5.5 KRAS and PI3K Mutation; 2.5.6 Microenvironment; 2.5.7 Epigenetic Changes; 2.5.8 Other Factors; 2.6 Toxicity and Tolerance; 2.7 Conclusions and New Frontiers in Drug Discovery; References; Chapter 3: c-MET in Head and Neck Squamous Cell Carcinoma; 3.1 Introduction; 3.2 c-MET Structure and Normal Function | |
| 505 | 8 | |a 3.2.1 c-MET General Structure3.2.2 c-MET Ligand: HGF/SF; 3.2.3 c-MET Trafficking; 3.2.4 c-MET-Associated Signaling; 3.3 c-MET Critical Interactions and Functions; 3.3.1 c-MET and the Epidermal Growth Factor (EGF) Family of Receptors; 3.3.2 c-MET and SRC; 3.3.3 c-MET in Epithelial-to-Mesenchymal Transition (EMT); 3.4 Dysregulation of HGF/c-MET in HNSCC; 3.4.1 c-MET Overexpression and Amplification; 3.4.2 c-MET Mutation; 3.4.3 Microenvironment and HGF/SF; 3.5 Clinical Applications of HGF/c-MET-Targeted Therapy; 3.5.1 Foretinib; 3.5.2 Tivantinib; 3.5.3 Additional Small-Molecule Inhibitors | |
| 520 | |a This book will benefit researchers interested in better understanding the biology of squamous cell cancers of the head and neck (SCCHN), with the goals of designing therapies, identifying risk factors and investigating the molecular basis of the disease. | ||
| 650 | 0 | |a Head |x Cancer |x Diagnosis. | |
| 650 | 0 | |a Neck |x Cancer |x Diagnosis. | |
| 650 | 0 | |a Head |x Cancer |x Treatment. | |
| 650 | 0 | |a Neck |x Cancer |x Treatment. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Head |x Cancer |x Diagnosis. |2 fast |0 (OCoLC)fst01767338 | |
| 650 | 7 | |a Head |x Cancer |x Treatment. |2 fast |0 (OCoLC)fst00952589 | |
| 650 | 7 | |a Neck |x Cancer |x Diagnosis. |2 fast |0 (OCoLC)fst01767425 | |
| 650 | 7 | |a Neck |x Cancer |x Treatment. |2 fast |0 (OCoLC)fst01035351 | |
| 650 | 7 | |a Oncology. |2 bicssc | |
| 650 | 7 | |a Proteins. |2 bicssc | |
| 650 | 1 | 4 | |a Cancer Research. |0 http://scigraph.springernature.com/things/product-market-codes/B11001 |
| 650 | 2 | 4 | |a Oncology. |0 http://scigraph.springernature.com/things/product-market-codes/H33160 |
| 650 | 2 | 4 | |a Protein Science. |0 http://scigraph.springernature.com/things/product-market-codes/L14040 |
| 655 | 4 | |a Electronic books. | |
| 700 | 1 | |a Burtness, Barbara, |e editor. |0 http://id.loc.gov/authorities/names/n2014187697 | |
| 700 | 1 | |a Golemis, Erica, |e editor. |0 http://id.loc.gov/authorities/names/n2001014471 | |
| 776 | 0 | 8 | |i Print version: |t Molecular determinants of head and neck cancer. |b Second edition. |d Cham : Humana Press, 2018 |z 3319787616 |z 9783319787619 |w (OCoLC)1027116046 |
| 830 | 0 | |a Current cancer research. |0 http://id.loc.gov/authorities/names/n2010184584 | |
| 880 | 8 | |6 505-00/(S |a 3.5.4 Antibodies Targeting c-MET3.5.5 Antibodies Targeting HGF/SF; 3.6 Conclusions and Future Directions; References; Chapter 4: Transforming Growth Factor Beta (TGF-β) Signaling in Head and Neck Squamous Cell Carcinoma (HNSCC); 4.1 Introduction; 4.2 TGF-β Signaling; 4.2.1 Canonical TGF-β Signaling; 4.2.2 Noncanonical TGF-β Signaling; 4.3 TGF-β Dysfunction in HNSCC; 4.3.1 TGF-β Ligands in HNSCC; 4.3.1.1 TGF-β Ligands: Model Systems; 4.3.1.2 TGF-β Ligands: Clinical Specimens; 4.3.1.3 TGF-β Ligands: Cancer Stem Cells; 4.3.2 TGF-β Receptors in HNSCC; 4.3.2.1 TGF-β Receptors: Model Systems | |
| 880 | 8 | |6 505-00/(S |a 4.3.2.2 TGF-β Receptors: Clinical Specimens | |
| 880 | 8 | |6 505-00/(S |a 2.3.2 Alternative Forms of EGFR and Its Effectors Affecting Signaling Activity in SCCHN2.3.3 Consequences of EGF/ErbB Activation; 2.3.3.1 Ras/Raf/MAPK; 2.3.3.2 PI3K/Akt/mTOR; 2.3.3.3 STAT; 2.3.3.4 PLC/PKC; 2.3.3.5 Src; 2.3.3.6 Nuclear Factor-κB (NF-κB); 2.3.3.7 Cyclin D1; 2.4 EGFR and Targeted Inhibitors; 2.4.1 Monoclonal Antibodies Targeting EGFR and Other ErbB Proteins; 2.4.1.1 Cetuximab; 2.4.1.2 Additional EGFR-Targeting Antibodies; 2.4.1.3 Monoclonal Antibodies Targeting Other ErbB Proteins; 2.4.2 Tyrosine Kinase Inhibitors (TKIs) Targeting EGFR and Other ErbB Proteins | |
| 903 | |a HeVa | ||
| 929 | |a oclccm | ||
| 999 | f | f | |i ac801784-5611-5ee9-8221-9d9230d046ee |s fb257e79-834e-512d-8819-d565f8ca07ca |
| 928 | |t Library of Congress classification |a RC280.H4 |l Online |c UC-FullText |u https://link.springer.com/10.1007/978-3-319-78762-6 |z Springer Nature |g ebooks |i 12555410 | ||